I
Immix Biopharma, Inc.
Period
FY 2025
Revenue
—
Net Income
$-29.40M
Total Assets
$104.84M
Equity
$93.80M
Shares Out
54.41M
Op. Cash Flow
$-23.93M
Business
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing chimeric antigen receptor T-cell (CAR-T) therapies, with its lead candidate NXC-201 in Phase 1b/2 trials for relapsed/refractory light chain amyloidosis. The company's N-GENIUS platform generates next-generation CAR-T cell therapies targeting B-cell maturation antigen (BCMA) for hematologic, neurologic, and other serious diseases. NXC-201 has received FDA Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), and Orphan Drug designations, with clinical development supported by contract manufacturing and a California Institute for Regenerative Medicine grant. The company operates through its subsidiary Nexcella, Inc. and pursues development in the United States and ex-U.S. markets.
Summary from 10-K filed 2026-03-25
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| General and administrative expenses | 14 | 11 | 7 | 4 | 1 | |
| Research and development | 16 | 11 | 9 | 4 | 126,527 | |
| Total operating expenses | 30 | 23 | 16 | 8 | 1 | |
| Loss from operations | −30 | −23 | −16 | −8 | −1 | |
| Interest income | 555,526 | 1 | 572,006 | — | — | |
| Total other income | 555,526 | 1 | 572,006 | −497 | −23 | |
| Loss before provision for income taxes | −29 | −22 | −16 | −8 | −24 | |
| Provision for income taxes | 37,724 | 41,037 | 26,415 | 10,268 | 6,013 | |
| Net loss | −29 | −22 | −16 | −8 | −24 | |
| Net loss attributable to non-controlling interests | — | 84,987 | 169,474 | — | — | |
| Net loss attributable to Immix Biopharma, Inc. common stockholders | −29 | −22 | −15 | −8 | −24 | |
| Foreign currency translation | 61,216 | −135,722 | 47,645 | −38,387 | −6,453 | |
| Total other comprehensive income (loss) | 61,216 | −135,722 | 47,645 | −38,387 | −6,453 | |
| Comprehensive loss | −29 | −22 | −15 | — | — | |
| Loss per common share - basic | −0.89 | −0.76 | −0.89 | −0.59 | −6.64 | |
| Loss per common share - diluted | −0.89 | −0.76 | −0.89 | −0.59 | — | |
| Weighted average shares outstanding - basic | 33 | 28 | 17 | 14 | 4 | |
| Weighted average shares outstanding - diluted | 33 | 28 | 17 | 14 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 94 | 18 | 18 | 13 | 18 | |
| Short-term investments | 7 | — | — | — | — | |
| Tax receivable | — | 2 | 1 | 255,705 | 25,722 | |
| Prepaid expenses and other current assets | 828,329 | 541,510 | 1 | 1 | 516,193 | |
| Total current assets | 101 | 20 | 20 | 15 | 18 | |
| Other assets | 20,418 | 20,418 | — | 6,724 | — | |
| Deferred offering costs | 93,630 | — | 87,229 | 6,724 | — | |
| Right-of-use asset, net | 966,917 | 989,471 | — | — | — | |
| Property and equipment, net | 3 | 2 | 50,181 | 3,560 | 5,695 | |
| Total assets | 105 | 23 | 20 | 15 | 18 | |
| Accounts payable and accrued expenses | 10 | 9 | 4 | 1 | 142,940 | |
| Operating lease liabilities - current | 139,339 | 65,219 | — | — | — | |
| Total current liabilities | 10 | 9 | 4 | 1 | 202,039 | |
| Operating lease liabilities - long term | 933,625 | 1 | — | — | — | |
| Total liabilities | 11 | 10 | 4 | 2 | 202,039 | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding | — | — | — | — | — | |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 53,023,466 shares issued and 52,951,103 shares outstanding at December 31, 2025, and 27,612,383 shares issued and 27,540,020 shares outstanding at December 31, 2024 | 5,301 | 2,762 | 2,000 | 1,397 | 1,323 | |
| Additional paid-in capital | 198 | 88 | 70 | 51 | 48 | |
| Accumulated other comprehensive income | 60,160 | −1,056 | 134,666 | 87,021 | 125,408 | |
| Accumulated deficit | −105 | −75 | −53 | −38 | −30 | |
| Treasury stock at cost, 72,363 shares as of December 31, 2025, and 2024 | −99,963 | −99,963 | — | — | — | |
| Total stockholders equity | 94 | 13 | 16 | 13 | 18 | |
| Total liabilities and stockholders equity | 105 | 23 | 20 | 15 | 18 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 2 | 3 | 3 | 624,069 | 218,983 | |
| Depreciation | 245,747 | 32,941 | 5,468 | 2,135 | 2,468 | |
| Amortization of right of use asset | 118,754 | 82,447 | — | — | — | |
| Tax receivable | 2 | −971,527 | −893,401 | −236,384 | 97,667 | |
| Prepaid expenses and other current assets | −286,729 | 554,770 | 111,842 | −691,047 | −502,795 | |
| Other assets | — | −20,418 | — | — | — | |
| Accounts payable and accrued expenses | 1 | 4 | 2 | — | — | |
| Operating lease liability | −98,006 | 2,852 | — | — | — | |
| Net cash used in operating activities | −24 | −15 | −11 | −7 | −2 | |
| Purchase of property and equipment | −732,925 | −1 | −52,089 | — | −802 | |
| Purchase of short-term investments | −6 | — | — | — | — | |
| Net cash used in investing activities | −7 | −1 | −52,089 | — | −802 | |
| Payments of deferred offering costs | −136,999 | — | −234,616 | −6,724 | — | |
| Proceeds from exercise of stock options | 6,342 | 2,489 | 2,618 | — | — | |
| Proceeds from exercise of stock warrants | 124,800 | — | — | — | — | |
| Proceeds from sale of common stock, net of offering costs | 107 | 16 | 16 | 3 | 19 | |
| Net cash provided by financing activities | 107 | 16 | 15 | 3 | 19 | |
| Effect of foreign currency on cash | 3,842 | −3,622 | 33,092 | −31,524 | −5,433 | |
| Net change in cash and cash equivalents | 76 | 172,163 | 4 | −4 | 17 | |
| Interest paid | — | — | — | 9,596 | 1,542 | |
| Income taxes paid | — | — | — | — | — | |
| Establishment of right of use asset and liabilities | 96,200 | 1 | — | — | — | |
| Purchases of property and equipment included in accounts payable and accrued liabilities | 294,294 | 545,229 | — | — | — | |
| Deferred offering costs charged against proceeds from sale of common stock | 43,369 | 87,229 | 147,387 | — | — | |
| Shares issues in subsidiary absorption | — | 99 | — | — | — | |
| Shares issued for vested RSUs | 26 | — | — | — | 28 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Immix Biopharma, Inc.'s CIK number?
Immix Biopharma, Inc.'s SEC CIK number is 0001873835 (1873835). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Immix Biopharma, Inc.'s SEC filings?
All of Immix Biopharma, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.